Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Branched-chain keto acids promote an immune-suppressive and neurodegenerative microenvironment in leptomeningeal disease.
Khaled ML, Ren Y, Kundalia R, Alhaddad H, Chen Z, Wallace GC, Evernden B, Ospina OE, Hall M, Liu M, Darville LNF, Izumi V, Chen YA, Pilon-Thomas S, Stewart PA, Koomen JM, Corallo SA, Jain MD, Robinson TJ, Locke FL, Forsyth PA, Smalley I. Khaled ML, et al. Among authors: pilon thomas s. bioRxiv [Preprint]. 2023 Dec 18:2023.12.18.572239. doi: 10.1101/2023.12.18.572239. bioRxiv. 2023. PMID: 38187773 Free PMC article. Preprint.
L-DOS47 enhances response to immunotherapy in pancreatic cancer tumor.
Jardim-Perassi BV, Irrera P, Abrahams D, Estrella VC, Ordway B, Byrne SR, Ojeda AA, Whelan CJ, Kim J, Beatty MS, Damgaci-Erturk S, Longo DL, Gaspar KJ, Siegers GM, Centeno BA, Lau JYC, Ibrahim-Hashim A, Pilon-Thomas SA, Gillies RJ. Jardim-Perassi BV, et al. Among authors: pilon thomas sa. bioRxiv [Preprint]. 2023 Aug 28:2023.08.28.555194. doi: 10.1101/2023.08.28.555194. bioRxiv. 2023. PMID: 37693389 Free PMC article. Updated. Preprint.
First-in-human stage III/IV melanoma​ clinical trial of immune priming agent IFx-Hu2.0.
Markowitz J, Shamblott M, Brohl AS, Sarnaik AA, Eroglu Z, Khushalani NI, Dukes CW, Chamizo A, Bastawrous M, Garcia ET, Delhawi A, Chen PL, De Aquino DB, Sondak VK, Tarhini AA, Kim Y, Lawman P, Pilon-Thomas S. Markowitz J, et al. Among authors: pilon thomas s. Mol Cancer Ther. 2024 Apr 24. doi: 10.1158/1535-7163.MCT-23-0652. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38657233
Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products.
Stewart MD, Kalos M, Coutinho V, Better M, Jazayeri J, Yohrling J, Jadlowsky J, Fuchs M, Gidwani S, Goessl C, Hanley PJ, Healy J, Liu W, McKelvey BA, Pearce L, Pilon-Thomas S, Andrews HS, Veldman M, Vong J, Weinbach SP, Allen JD. Stewart MD, et al. Among authors: pilon thomas s. Cytotherapy. 2024 Mar 16:S1465-3249(24)00097-5. doi: 10.1016/j.jcyt.2024.03.009. Online ahead of print. Cytotherapy. 2024. PMID: 38583170 Free article.
L-DOS47 Elevates Pancreatic Cancer Tumor pH and Enhances Response to Immunotherapy.
Jardim-Perassi BV, Irrera P, Oluwatola OE, Abrahams D, Estrella VC, Ordway B, Byrne SR, Ojeda AA, Whelan CJ, Kim J, Beatty MS, Damgaci-Erturk S, Longo DL, Gaspar KJ, Siegers GM, Centeno BA, Lau JYC, Pilon-Thomas SA, Ibrahim-Hashim A, Gillies RJ. Jardim-Perassi BV, et al. Among authors: pilon thomas sa. Biomedicines. 2024 Feb 19;12(2):461. doi: 10.3390/biomedicines12020461. Biomedicines. 2024. PMID: 38398062 Free PMC article.
Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients.
Dukes CW, Potez M, Lancet J, Kuter BJ, Whiting J, Mo Q, Leav B, Wang H, Vanas JS, Cubitt CL, Isaacs-Soriano K, Kennedy K, Rathwell J, Diaz Cobo J, O'Nan W, Sirak B, Dong N, Tan E, Hwu P, Giuliano AR, Pilon-Thomas S. Dukes CW, et al. Among authors: pilon thomas s. Vaccines (Basel). 2023 Dec 22;12(1):13. doi: 10.3390/vaccines12010013. Vaccines (Basel). 2023. PMID: 38250826 Free PMC article.
Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients.
Hall MS, Teer JK, Yu X, Branthoover H, Snedal S, Rodriguez-Valentin M, Nagle L, Scott E, Schachner B, Innamarato P, Hall AM, Blauvelt J, Rich CJ, Richards AD, Ceccarelli J, Langer TJ, Yoder SJ, Beatty MS, Cox CA, Messina JL, Abate-Daga D, Mule JJ, Mullinax JE, Sarnaik AA, Pilon-Thomas S. Hall MS, et al. Among authors: pilon thomas s. J Immunother Cancer. 2023 Oct;11(10):e007288. doi: 10.1136/jitc-2023-007288. J Immunother Cancer. 2023. PMID: 37802604 Free PMC article.
SARS-CoV-2 antibody response duration and neutralization following natural infection.
Dukes CW, Rossetti RA, Hensel JA, Snedal S, Cubitt CL, Schell MJ, Abrahamsen M, Isaacs-Soriano K, Kennedy K, Mangual LN, Whiting J, Martinez-Brockhus V, Islam JY, Rathwell J, Beatty M, Hall AM, Abate-Daga D, Giuliano AR, Pilon-Thomas S. Dukes CW, et al. Among authors: pilon thomas s. J Clin Virol Plus. 2023 Aug;3(3):100158. doi: 10.1016/j.jcvp.2023.100158. Epub 2023 Jul 1. J Clin Virol Plus. 2023. PMID: 37654784 Free PMC article.
87 results